Préservation de la fertilité, contraception et traitement hormonal de la ménopause chez les femmes traitées pour tumeurs malignes rares de l’ovaire : recommandations du réseau national dédié aux cancers gynécologiques rares (TMRG/GINECO)

Christine Rousset‐Jablonski, Frédèric Selle, Elodie Adda-Herzog, François Planchamp, Lise Selleret, Christophe Pomel, Nathalie Chabbert‐Buffet, Émile Daraï, Patricia Pautier, Florence Trémollières, Frédéric Guyon, Roman Rouzier, Valérie Laurence, Nicolás Chopin, Cécile Faure‐Conter, Enrica Bentivegna, Marie‐Cécile Vacher‐Lavenu, Catherine Lhommé, Anne Floquet, Isabelle Treilleux, Fabrice Lécuru, Sébastien Gouy, Elsa Kalbacher, Catherine Genestie, Thibault De La Motte Rouge, Gwénaël Ferron, Mojgan Devouassoux‐Shisheboran, Jean‐Emmanuel Kurtz, Moïse Namer, Florence Joly, Éric Pujade-Lauraine, Michaël Grynberg, Denis Querleu, Philippe Morice, Anne Gompel, Isabelle Ray‐CoquardBulletin 2018 · DOI

Introduction

Rare ovarian tumors—including borderline ovarian tumors (BOTs), germ cell tumors, and sex cord-stromal tumors—frequently affect women of reproductive age. The management of these patients presents a complex clinical intersection between oncology, endocrinology, and reproductive medicine. While life-saving treatments like surgery and chemotherapy are paramount, they often induce premature menopause or infertility, significantly impacting long-term quality of life. Clinicians face a persistent dilemma: how to manage hormonal needs (contraception, HRT) and fertility preservation without increasing the risk of tumor recurrence, particularly in hormone-sensitive subtypes.

Methodology: The Delphi Consensus

Given the rarity of these conditions, large-scale randomized controlled trials—the gold standard of clinical evidence—are largely absent. To address this gap, the TMRG/GINECO national network convened a panel of 35 French experts across oncology, surgery, gynecology, reproductive medicine, and pathology.

The panel utilized the Delphi method, a structured communication technique designed to reach a formal consensus when literature is scarce. Following a systematic review of available case series and retrospective cohorts, the experts engaged in two rounds of anonymous rating. A "strong agreement" was reached for 35 specific recommendations, defined by high median scores and a lack of extreme outliers in the voting distribution.

Risk Stratification by Hormone Sensitivity

The cornerstone of these guidelines is the categorization of risk based on the biological hormone-sensitivity of the specific tumor type. This framework allows clinicians to move away from a "one-size-fits-all" approach.

1. Hormone-Insensitive (The "Safe" Zone)

Germ Cell Tumors are generally considered hormone-insensitive. For survivors of these tumors, the panel concluded that hormone replacement therapy (HRT), hormonal contraception, and controlled ovarian stimulation (COS) for fertility preservation are safe and should not be restricted.

2. Variable Sensitivity (The "Caution" Zone)

Borderline Ovarian Tumors (BOTs) represent a middle ground. While most BOTs allow for standard hormonal management, the presence of "high-risk" features—such as invasive peritoneal implants or micropapillary patterns—necessitates a cautious, case-by-case multidisciplinary approach.

3. Hormone-Sensitive (The "Danger" Zone)

Sex Cord-Stromal Tumors (e.g., adult granulosa cell tumors) and Low-Grade Epithelial Subtypes (e.g., low-grade serous adenocarcinomas) are highly hormone-sensitive. In these cases, estrogen-containing treatments are generally contraindicated. Exceptions may only be discussed for very early-stage disease (Stage IA/IB) within a multidisciplinary setting.

Key Clinical Recommendations

The consensus yielded 35 formal recommendations, focusing on three primary areas:

  • Fertility Preservation: Ovarian stimulation followed by oocyte or embryo vitrification is the preferred strategy. However, it is contraindicated in most hormone-sensitive rare epithelial and sex cord tumors due to the potential risks associated with high gonadotropin or estrogen levels.
  • Contraception: Combined estroprogestin options should be avoided during active cancer treatment to mitigate thromboembolic risks. For long-term use in hormone-sensitive survivors, progestin-only options are recommended as a safer alternative.
  • Hormone Replacement Therapy (HRT): HRT is strongly recommended for survivors of germ cell tumors and most BOTs to prevent the long-term morbidities of premature menopause, such as cardiovascular disease and osteoporosis. Conversely, HRT is generally avoided in low-grade serous or endometrioid cancers unless the disease was caught at an extremely early stage.

Limitations and Future Directions

The authors acknowledge that these recommendations are primarily based on expert opinion and limited retrospective data. The inherent uncertainty of expert consensus highlights the need for more robust evidence. Future efforts should prioritize the development of international registries to pool data on these rare cohorts, specifically focusing on the long-term safety of HRT and pregnancy outcomes following assisted reproductive technology.

Summary updated

BibTeX
@article{roussetjablonski2018preservation,
  author = {Christine Rousset‐Jablonski and Frédèric Selle and Elodie Adda-Herzog and François Planchamp and Lise Selleret and Christophe Pomel and Nathalie Chabbert‐Buffet and Émile Daraï and Patricia Pautier and Florence Trémollières and Frédéric Guyon and Roman Rouzier and Valérie Laurence and Nicolás Chopin and Cécile Faure‐Conter and Enrica Bentivegna and Marie‐Cécile Vacher‐Lavenu and Catherine Lhommé and Anne Floquet and Isabelle Treilleux and Fabrice Lécuru and Sébastien Gouy and Elsa Kalbacher and Catherine Genestie and Thibault De La Motte Rouge and Gwénaël Ferron and Mojgan Devouassoux‐Shisheboran and Jean‐Emmanuel Kurtz and Moïse Namer and Florence Joly and Éric Pujade-Lauraine and Michaël Grynberg and Denis Querleu and Philippe Morice and Anne Gompel and Isabelle Ray‐Coquard},
  title = {{Préservation de la fertilité, contraception et traitement hormonal de la ménopause chez les femmes traitées pour tumeurs malignes rares de l’ovaire : recommandations du réseau national dédié aux cancers gynécologiques rares (TMRG/GINECO)}},
  journal = {Bulletin},
  year = {2018},
  doi = {10.1016/j.bulcan.2017.10.032},
}
Figure